Rein Therapeutics Inc. (RNTX)
| Market Cap | 40.66M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -49.87M |
| Shares Out | 28.04M |
| EPS (ttm) | -1.96 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 210,701 |
| Open | 1.500 |
| Previous Close | 1.490 |
| Day's Range | 1.370 - 1.520 |
| 52-Week Range | 1.020 - 2.400 |
| Beta | 1.40 |
| Analysts | Buy |
| Price Target | 10.00 (+589.66%) |
| Earnings Date | May 14, 2026 |
About RNTX
Rein Therapeutics Inc., a biopharmaceutical company, focuses on developing medicines to address unmet medical needs in orphan pulmonary and fibrosis indications in the United States. The company’s lead product candidate is LTI-03, a peptide, which is in Phase 1b clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF). It also offers LTI-01, a proenzyme that has completed Phase 1b and Phase 2a clinical trials in LPE patients for the treatment of loculated pleural effusion. The company’s pipeline also includes preclinical programs... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 2 analysts, the average rating for RNTX stock is "Buy." The 12-month stock price target is $10.0, which is an increase of 589.66% from the latest price.
News
Why Is Rein Therapeutics Stock Trading Higher On Monday?
Rein Therapeutics (NASDAQ:RNTX) stock is trading higher on Monday, with a session volume of 41.2 million compared to its average volume of 162.67 thousand, according to data from Benzinga Pro.
Rein Therapeutics Receives European Regulatory Approval to Initiate Phase 2 Trial of LTI-03 in Idiopathic Pulmonary Fibrosis
AUSTIN, Texas, Oct. 09, 2025 (GLOBE NEWSWIRE) -- Rein Therapeutics ("Rein") (NASDAQ: RNTX), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant un...
Rein Therapeutics Announces Publication of New Translational Data in iScience on Company's Novel Therapy for Idiopathic Pulmonary Fibrosis
AUSTIN, Texas, Sept. 17, 2025 (GLOBE NEWSWIRE) -- Rein Therapeutics ("Rein") (NASDAQ: RNTX), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant u...
Rein Therapeutics Wins U.K. Approval to Launch Phase 2 Clinical Trial of LTI-03 in Idiopathic Pulmonary Fibrosis
AUSTIN, Aug. 19, 2025 (GLOBE NEWSWIRE) -- Rein Therapeutics ("Rein") (NASDAQ: RNTX), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet med...
Rein Therapeutics to Present Novel IPF Science and Clinical Development Insights at IPF Summit 2025
AUSTIN, Texas, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Rein Therapeutics ("Rein") (NASDAQ: RNTX), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant un...
Rein Therapeutics Transcript: AGM 2025
The meeting confirmed a quorum, elected a Class II Director, and approved executive compensation. No questions were raised by stockholders, and all formal business was completed virtually. Final voting results will be filed in Form 8-K.
Rein Therapeutics Announces Adjournment of Annual Meeting of Stockholders
Meeting adjourned to Wednesday, July 23, 2025 at 9:00 a.m. Eastern Time AUSTIN, Texas , June 24, 2025 /PRNewswire/ -- Rein Therapeutics ("Rein") (NASDAQ: RNTX), a biopharmaceutical company advancing a...
US FDA puts on hold Rein Therapeutics' lung disease drug trial
Rein Therapeutics has paused patient enrollment and dosing in a mid-stage trial of its lung disease drug in the U.S. after the Food and Drug Administration placed a clinical hold, the drug developer s...
Rein Therapeutics Announces First Patient Dosed in RENEW Phase 2 Trial of LTI-03 in Patients with IPF
Trial is evaluating the safety, tolerability, and efficacy of LTI-03 in idiopathic pulmonary fibrosis (IPF) with topline interim data expected in the first half of 2026 AUSTIN, Texas , May 27, 2025 /P...
Rein Therapeutics Presents Two Posters at the American Thoracic Society 2025 International Conference
Presentations further support the dual mechanism of LTI-03 and the development of Cav1-related peptides for the treatment of idiopathic pulmonary fibrosis (IPF) Company recently initiated RENEW Phase ...
Rein Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
RENEW Phase 2 trial evaluating the safety, tolerability, and efficacy of LTI-03 in idiopathic pulmonary fibrosis (IPF) initiated with topline interim data expected in the first half of 2026 Two abstra...
Rein Therapeutics Announces Initiation of RENEW Phase 2 Trial of LTI-03 in Patients with IPF
The RENEW Phase 2 trial will enroll up to 120 IPF patients with topline data expected in the first half of 2026 In the previously reported Phase 1b study, LTI-03 showed a positive trend in seven out o...
Rein Therapeutics Transcript: The Citizens JMP Life Sciences Conference 2025
The conference highlighted two phase two assets targeting severe pulmonary conditions, with LTI-O3 showing strong antifibrotic and regenerative effects in IPF and poised for a pivotal trial. Early biomarker and safety data are promising, with key lung function results expected next year.
Rein Therapeutics and Qureight Ltd Announce Planned Integration of Deep-Learning Platform for Phase 2 Trial of LTI-03 in Patients with IPF
AUSTIN, Texas , May 1, 2025 /PRNewswire/ -- Rein Therapeutics ("Rein") (NASDAQ: RNTX), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet m...
Rein Therapeutics to Present at The Citizens Life Sciences Conference 2025
AUSTIN, Texas , April 30, 2025 /PRNewswire/ -- Rein Therapeutics ("Rein") (NASDAQ: RNTX), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unme...
Rein Therapeutics Announces Abstract Accepted for Presentation at the American Thoracic Society 2025 International Conference
AUSTIN, Texas , April 28, 2025 /PRNewswire/ -- Rein Therapeutics ("Rein") (NASDAQ: RNTX), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unme...
Rein Therapeutics Granted Two Patents Covering the Novel Formulation and Administration Methods of Dry Powder LTI-03 for the Treatment of Respiratory Diseases
AUSTIN, Texas , April 23, 2025 /PRNewswire/ -- Rein Therapeutics ("Rein") (NASDAQ: RNTX), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unme...
Rein Therapeutics Announces a Publication in Biomedicines on the Immunomodulatory and Anti-fibrotic Properties of a Caveolin-1-Related Peptide in IPF and PASC-F
Manuscript highlights the effects of caveolin scaffolding domain peptide LTI-2355 on myeloid cell activity in Idiopathic Pulmonary Fibrosis (IPF) and Post-Acute Sequelae of COVID Fibrosis (PASC-F) AUS...
Rein Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
Rein advanced the clinical development of its lead asset, LTI-03, and aims to initiate a Phase 2 trial for the treatment of idiopathic pulmonary fibrosis (IPF) in the first half of 2025 Positive topli...
Rein Therapeutics Transcript: Study Result
A 14-day phase I-B trial of LTI-03 in IPF patients showed dose-dependent, statistically significant reductions in key pro-fibrotic and epithelial biomarkers, with a favorable safety profile and no major adverse events. These results support advancing to phase II.
Rein Therapeutics Transcript: Canaccord Genuity 44th Annual Growth Conference & Private Company Showcase 2024
LTI-03, a novel peptide therapy for IPF, shows both anti-fibrotic and regenerative effects, with promising safety and biomarker results in early clinical trials. The drug targets a large unmet market and may expand into other fibrotic lung diseases.